| Suggest |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Health and Fitness > Depression > Depression is the Number One Cause of Disability in the United States |
|
Suggest - Depression is the Number One Cause of Disability in the United States
According to the World Health Organization, 4 of the 10 leading causes of disa According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product bility in the United States and other developed countries are mental disorder ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in s, including major depression, bipolar disorder, and schizophrenia. Approximately lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. 23% of American adults each year have a diagnosable mental disorder and as many here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe as 5.4% of American adults have a serious mental illness. Depression has receive d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro increased attention recently because of the growing recognition of itsprevalence ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc . Once misunderstood and stigmatized, depression now is regarded as a biological easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi condition. Management of depressed patients increasingly involves healthcare prof nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically essionals other than psychiatrists. To assist these healthcare professionals, thi and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ s article provides a basic description of depression and describes currently avai ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi able pharmacotherapies for treating depression, including selective serotonin reu ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ptake inhibitors (SSRIs) Neurostimulation is the next frontier in the treatment dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod of chronic depression. The FDA is expected to approve vagus nerve stimulation as cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin a treatment for chronic depression within the next thirty days. You can learn mor tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen e about this remarkable therapy at http://www.VagusNerveStimulator.com Vagus ner t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel e stimulation is a ninety-minute out-patient procedure performed by a surgeon. A ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust prescription by your psychiatrist is required. The vagus nerve stimulator is pace y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products maker-like device implanted in the patient's upper left chest. One lead wire is t . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de unneled underneath the skin and coiled around the left vagus nerve in the neck. I elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip t is not related to brain surgery or shock therapy and is more effective than ECT tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:I Have Health Insurance, Now Help Me Understand My Policy
|